Characteristic | Number of studies* (n=208) | Percentage of studies |
---|---|---|
Year of publication | ||
1989–1994 | 3 | 1.4 |
1995–1999 | 15 | 7.2 |
2000–2004 | 35 | 16.8 |
2005–2009 | 68 | 32.7 |
2010–2014 | 87 | 41.8 |
Geographic region | ||
Europe | 72 | 34.6 |
Multicontinent | 44 | 21.2 |
North America | 36 | 17.3 |
Multicountry (not specified) | 24 | 11.5 |
Asia | 20 | 9.6 |
Not reported | 9 | 4.3 |
Africa | 1 | 0.5 |
Australia | 1 | 0.5 |
South America | 1 | 0.5 |
Setting | ||
Single centre | 32 | 15.4 |
Multicentre | 152 | 73.1 |
Not reported | 24 | 11.5 |
Duration of follow-up† | ||
0 to ≤6 | 45 | 21.6 |
>6 to ≤12 | 52 | 25 |
>12 to ≤24 | 35 | 16.8 |
>24 to ≤48 | 19 | 9.1 |
>48 to ≤72 | 39 | 18.8 |
>72 to ≤96 | 2 | 1 |
>96 to ≤120 | 6 | 2.9 |
>120 weeks | 9 | 4.3 |
Not reported | 1 | 0.5 |
Outcomes examined: frequency‡ | ||
Efficacy—exacerbations | 112 | 53.8 |
Efficacy—mortality | 95 | 45.7 |
Harm—cardiovascular-related mortality | 46 | 22.1 |
Harm—pneumonia | 54 | 26.0 |
Harm—arrhythmia | 32 | 15.4 |
*Includes unpublished data.
†Duration is in weeks unless otherwise noted.
‡Multiple interventions and outcomes reported per study.